V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10000298 | 10065414 | 1.75 | 68.2 | 03 | 2020-01-18 | 2020-01-27 | CARFILZOMIB | 02 | N | CYTARABINE + METHOTREXATE | 101244197 |
| 10001902 | 10065415 | 1.7 | 63.4 | Adjuvant (A) | 2021-07-27 | 2021-07-30 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | BEVACIZUMAB | 101754306 |
| 10025690 | 10065419 | 0 | 78 | null | null | 2021-08-06 | null | 02 | null | IXAZOMIB | 100195169 |
| 10040757 | 10065420 | 1.62 | 70.7 | Palliative (P) | 2015-09-18 | 2015-09-18 | Gefitinib: 1 to 2 & 4 onwards | 02 | N | NERATINIB | 101688093 |
| 10057843 | 10065421 | 1.85 | 0 | null | 2020-02-14 | 2020-02-19 | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 02 | null | CAPECITABINE + MITOMYCIN | 101687648 |
| 10068099 | 10065423 | 1.8 | 64.7 | 03 | 2019-03-29 | 2019-03-29 | Capecitabine + Streptozocin | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100901461 |
| 10078746 | 10065424 | 1.69 | 76 | Palliative (P) | 2020-12-11 | 2020-12-11 | R CODOX-M/ R IVAC | 02 | N | RIBOCICLIB | 100686413 |
| 10088536 | 10065425 | 0 | 67.5 | Palliative (P) | 2020-07-16 | 2020-12-05 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | Y | N | ERLOTINIB | 100846154 |
| 10100529 | 10065428 | 1 | 0 | Disease modification (D) | 2022-01-18 | 2022-01-18 | MPV (cycle 5-9) - maintenance | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + PROCARBAZINE + VINCRISTINE | 101475996 |
| 10104573 | 10065430 | 1.64 | 84 | null | 2018-12-21 | 2019-01-04 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | ALEMTUZUMAB | 100510185 |
| 10115321 | 10065431 | 1.98 | 71.7 | Palliative (P) | 2021-04-11 | 2021-04-14 | null | 01 | N | BENDAMUSTINE + OBINUTUZUMAB | 101842694 |
| 10133733 | 10065432 | 1.58 | 70.2 | Adjuvant (A) | 2019-12-02 | 2019-12-02 | Bevacizumab + Olaparib | null | N | OBINUTUZUMAB | 101578948 |
| 10137589 | 10065433 | 1.75 | 91 | Neo-adjuvant (N) | 2020-03-27 | 2020-04-25 | null | 02 | Y | IDELALISIB + RITUXIMAB | 100966751 |
| 10144014 | 10065435 | 1.6 | 90 | 03 | 2018-09-08 | 2021-04-25 | null | 02 | N | BEXAROTENE | 100732259 |
| 10161782 | 10065442 | null | null | null | null | 2017-07-19 | Doxorubicin + Ifosfamide | 02 | null | OCTREOTIDE | 101686103 |
| 10167078 | 10065444 | 1.6 | 113 | Curative (C) | 2018-02-18 | 2018-03-27 | RIALTO TRIAL | 02 | N | STAMPEDE TRIAL | 100442281 |
| 10172452 | 10065445 | null | null | Curative (C) | 2011-04-08 | 2017-05-12 | Cytarabine Low Dose | null | N | DOXORUBICIN + OLARATUMAB | 100916754 |
| 10175206 | 10065446 | 1.58 | 80 | Palliative (P) | 2019-06-19 | 2019-11-11 | LORLATINIB | null | N | CHOP | 101115525 |
| 10175282 | 10065447 | 1.66 | 60.2 | null | 2017-09-29 | 2017-10-09 | RIALTO TRIAL | 02 | null | BRENTUXIMAB | 101574796 |
| 10175292 | 10065448 | 1.53 | 83.2 | Palliative (P) | 2018-08-28 | 2018-09-14 | PANOBINOSTAT | 02 | N | CHLORAMBUCIL + RITUXIMAB | 100834633 |
| 10179413 | 10065454 | 0 | 52.3 | Palliative (P) | 2020-03-29 | 2020-04-01 | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE + TREOSULFAN | 02 | N | MUK8 TRIAL | 101002447 |
| 10181064 | 10065455 | 1.52 | 118 | null | 2019-09-19 | 2019-10-16 | BENDAMUSTINE + Brentuximab Vendotin | 02 | null | TRABECTEDIN | 100920622 |
| 10183908 | 10065456 | 0 | 81.2 | Palliative (P) | 2020-01-09 | 2020-01-13 | Gemcitabine + Oxaliplatin | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 100408669 |
| 10184123 | 10065457 | 0 | 68 | Curative (C) | 2020-06-26 | 2020-07-15 | Cladribine + Rituximab | 02 | null | CYTARABINE + METHOTREXATE + RITUXIMAB | 100164493 |
| 10184510 | 10065458 | 1.7 | 82.7 | Adjuvant (A) | null | 2020-01-28 | MPT | 02 | N | BOSUTINIB | 101551993 |
| 10185049 | 10065459 | 0 | 75 | null | 2017-11-01 | 2017-11-12 | ISATUXIMAB + POMALIDOMIDE | 02 | null | BEXAROTENE | 100990781 |
| 10185705 | 10065460 | 1.88 | 73 | Palliative (P) | 2018-06-20 | 2018-06-21 | MYELOMA XI TRIAL | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101518830 |
| 10186892 | 10065461 | 1.66 | 73 | Palliative (P) | 2018-08-15 | 2018-08-20 | CLARITY Trial | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100272932 |
| 10187101 | 10065462 | 1.58 | 76 | null | null | 2020-03-08 | Vinblastine | 02 | null | BINIMETINIB + ENCORAFENIB | 100147820 |
| 10187561 | 10065464 | 1.56 | 107.4 | Adjuvant (A) | 2020-02-07 | 2020-02-07 | MPV (cycle 1-4) | 02 | N | CISPLATIN + FLUOROURACIL | 100487904 |
| 10188203 | 10065465 | 1.7 | 58.8 | null | 2022-05-02 | 2022-05-14 | CAPECITABINE + CARBOPLATIN | 02 | null | NOT MATCHED | 101412489 |
| 10189203 | 10065466 | null | null | Adjuvant (A) | 2020-02-25 | 2021-07-17 | IDELALISIB + RITUXIMAB | 02 | null | APALUTAMIDE | 100076185 |
| 10193984 | 10065469 | 1.53 | 80.8 | Palliative (P) | 2018-09-22 | 2018-10-07 | Fulvestrant + Ribociclib | 02 | N | DOXORUBICIN + OLARATUMAB | 100028567 |
| 10194595 | 10065470 | 1.63 | 68.25 | null | 2019-10-30 | 2019-10-30 | null | 02 | null | CAPECITABINE + MITOMYCIN | 100647434 |
| 10196455 | 10065473 | 1.64 | 40.3 | null | 2020-06-02 | 2020-10-11 | null | 02 | null | CLARITY TRIAL | 101072402 |
| 10202044 | 10065479 | 1.7 | 63 | null | 2017-05-17 | 2018-03-09 | DA-EPOCH-R | 2 | null | ANTI-THYMOCYTE GLOBULIN + BUSULFAN + FLUDARABINE | 101073860 |
| 10208849 | 10065483 | 1.83 | 89 | null | 2021-04-13 | 2021-04-13 | null | 02 | null | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 100114234 |
| 10209860 | 10065484 | null | null | 03 | 2020-01-14 | 2020-01-27 | LEAM | 02 | N | ABVD | 101658124 |
| 10210860 | 10065485 | 1.68 | 64 | Palliative (P) | 2017-01-08 | 2017-01-18 | Carboplatin + Docetaxel | 02 | N | PARTNER TRIAL | 100412249 |
| 10212602 | 10065487 | 1.79 | null | null | 2017-08-19 | 2019-12-30 | Obinutuzumab + Venetoclax | 02 | null | CARFILZOMIB | 100779482 |
| 10226663 | 10065491 | 1.62 | 81.3 | Palliative (P) | 2022-01-13 | 2022-01-13 | VISMODEGIB | 99 | N | ANAGRELIDE | 101699506 |
| 10228933 | 10065494 | 1.67 | 80.6 | Adjuvant (A) | 2020-02-18 | 2020-02-19 | null | 02 | N | BOSUTINIB | 101397469 |
| 10240488 | 10065495 | 1.52 | 0 | Adjuvant (A) | 2019-09-24 | 2019-09-28 | EVEROLIMUS | 02 | N | FULVESTRANT + RIBOCICLIB | 101791713 |
| 10240910 | 10065496 | 1.64 | 92 | 03 | 2019-06-18 | 2019-06-19 | EVEROLIMUS | 02 | N | MITOMYCIN | 101674103 |
| 10245092 | 10065498 | 1.6 | 65.4 | Palliative (P) | 2016-04-27 | 2016-04-27 | FCR Oral - Cycle 1 | 02 | N | LIPOSOMAL DOXORUBICIN | 100537325 |
| 10251295 | 10065500 | 1.63 | 71.6 | Neo-adjuvant (N) | 2020-02-10 | 2020-05-20 | null | 02 | N | IRINOTECAN + MDG | 100189616 |
| 10257267 | 10065501 | 1.7 | 64.7 | Palliative (P) | 2020-06-08 | 2020-06-11 | CARFILZOMIB | 01 | N | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 101351999 |
| 10257579 | 10065502 | 1.88 | 88.8 | null | 2021-03-17 | 2021-03-17 | VISMODEGIB | 02 | null | DOXORUBICIN + OLARATUMAB | 101654023 |
| 10273139 | 10065505 | 1.69 | 0 | null | 2017-10-18 | 2019-10-14 | BOSUTINIB | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100864854 |
| 10275881 | 10065510 | 1.72 | 96.2 | null | 2020-10-01 | 2020-10-30 | BRIGATINIB | null | null | MATRIX LYMPHOMA TRIAL | 100035992 |